GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » EBITDA Margin %

Genetic Signatures (ASX:GSS) EBITDA Margin % : -314.10% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genetic Signatures's EBITDA for the six months ended in Dec. 2023 was A$-11.32 Mil. Genetic Signatures's Revenue for the six months ended in Dec. 2023 was A$3.60 Mil. Therefore, Genetic Signatures's EBITDA margin for the quarter that ended in Dec. 2023 was -314.10%.


Genetic Signatures EBITDA Margin % Historical Data

The historical data trend for Genetic Signatures's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures EBITDA Margin % Chart

Genetic Signatures Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only -62.08 -10.39 11.37 13.26 -58.64

Genetic Signatures Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.92 -5.48 -59.30 -58.01 -314.10

Competitive Comparison of Genetic Signatures's EBITDA Margin %

For the Diagnostics & Research subindustry, Genetic Signatures's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Signatures's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's EBITDA Margin % falls into.



Genetic Signatures EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Genetic Signatures's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-12.525/21.36
=-58.64 %

Genetic Signatures's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-11.32/3.604
=-314.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Signatures  (ASX:GSS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Genetic Signatures EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Signatures (ASX:GSS) Business Description

Traded in Other Exchanges
N/A
Address
7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.